ATE216239T1 - Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden - Google Patents
Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschädenInfo
- Publication number
- ATE216239T1 ATE216239T1 AT97301172T AT97301172T ATE216239T1 AT E216239 T1 ATE216239 T1 AT E216239T1 AT 97301172 T AT97301172 T AT 97301172T AT 97301172 T AT97301172 T AT 97301172T AT E216239 T1 ATE216239 T1 AT E216239T1
- Authority
- AT
- Austria
- Prior art keywords
- tissue damage
- reductase inhibitor
- cardiological
- aldose reductase
- reduce non
- Prior art date
Links
- 229940118148 Aldose reductase inhibitor Drugs 0.000 title abstract 2
- 239000003288 aldose reductase inhibitor Substances 0.000 title abstract 2
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 title abstract 2
- 230000000451 tissue damage Effects 0.000 title abstract 2
- 231100000827 tissue damage Toxicity 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000005003 heart tissue Anatomy 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1270796P | 1996-02-29 | 1996-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE216239T1 true ATE216239T1 (de) | 2002-05-15 |
Family
ID=21756300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97301172T ATE216239T1 (de) | 1996-02-29 | 1997-02-21 | Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US6127367A (de) |
| EP (1) | EP0792643B1 (de) |
| JP (1) | JPH09316003A (de) |
| KR (1) | KR970061252A (de) |
| CN (1) | CN1081460C (de) |
| AT (1) | ATE216239T1 (de) |
| AU (1) | AU724327B2 (de) |
| CA (1) | CA2198564C (de) |
| DE (1) | DE69711972T2 (de) |
| DK (1) | DK0792643T3 (de) |
| ES (1) | ES2172748T3 (de) |
| IL (1) | IL120264A0 (de) |
| PT (1) | PT792643E (de) |
| ZA (1) | ZA971717B (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0982306A3 (de) * | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph von Zopolrestat Monohydrat |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2002098421A1 (en) * | 2001-06-05 | 2002-12-12 | University Of Maryland, Baltimore | Novel treatment for neurological and psychiatric disorders |
| AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| ES2393271T3 (es) * | 2005-12-16 | 2012-12-19 | Sanwa Kagaku Kenkyusho Co., Ltd | Agente para la prevención y tratamiento de la insuficiencia renal aguda |
| WO2007097301A1 (ja) * | 2006-02-20 | 2007-08-30 | Sanwa Kagaku Kenkyusho Co., Ltd. | 脳卒中における脳虚血又は脳虚血再灌流障害の予防又は治療剤 |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| EP2594267A1 (de) * | 2007-01-31 | 2013-05-22 | Sanwa Kagaku Kenkyusho Co., Ltd | Wirkstoff zum Schutz der Retinanerven oder der Sehnerven |
| EP2848252A3 (de) | 2007-03-23 | 2015-06-17 | The Board of Regents of the University of Texas System | Aldose-Reduktase-Inhibitoren zur Behandlung von Uveitis |
| JP2010539149A (ja) | 2007-09-14 | 2010-12-16 | アストラゼネカ アクチボラグ | フタラジノン誘導体 |
| JP5593229B2 (ja) | 2007-10-17 | 2014-09-17 | クドス ファーマシューティカルズ リミテッド | ４−［３−（４−シクロプロパンカルボニル−ピペラジン−１−カルボニル）−４−フルオロ−ベンジル］−２ｈ−フタラジン−１−オン |
| EP2220216A4 (de) * | 2007-11-15 | 2013-03-20 | Univ Laval | Verfahren zur regulation der prostaglandin f-synthase- (pgfs-)aktivität von akr1b1 und verwendungen davon |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
| ES2598178T5 (es) | 2008-10-07 | 2023-12-26 | Kudos Pharm Ltd | Formulación farmacéutica 514 |
| US8785483B2 (en) | 2010-12-23 | 2014-07-22 | The Board Of Regents Of The University Of Texas System | Methods for treating COPD |
| WO2018075192A1 (en) | 2016-10-19 | 2018-04-26 | Spectrum Brands, Inc. | Portable steam generator base for iron |
| US20240033263A1 (en) | 2021-03-18 | 2024-02-01 | Banavara MYLARI | Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications |
| KR102888312B1 (ko) * | 2022-09-07 | 2025-11-20 | 애니머스큐어 주식회사 | 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4492706A (en) * | 1983-08-01 | 1985-01-08 | American Home Products Corporation | Method of lowering lipid levels |
| US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| EP0310931A3 (de) * | 1987-10-08 | 1990-10-03 | Ethyl Corporation | Hühnerfutter |
| FR2665440B1 (fr) * | 1990-07-31 | 1994-02-04 | Lipha | Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant. |
| US5064830A (en) * | 1990-08-02 | 1991-11-12 | Pfizer Inc. | Lowering of blood uric acid levels |
| JP3049284B2 (ja) * | 1990-11-07 | 2000-06-05 | 株式会社三和化学研究所 | ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤 |
| US5391551A (en) * | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
| US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| AU711080B2 (en) * | 1994-12-22 | 1999-10-07 | Regents Of The University Of California, The | Method for protecting the heart from ischemia |
| CZ293016B6 (cs) * | 1995-06-01 | 2004-01-14 | Sankyo Company Limited | Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem |
-
1997
- 1997-02-20 US US08/803,301 patent/US6127367A/en not_active Expired - Fee Related
- 1997-02-20 IL IL12026497A patent/IL120264A0/xx not_active IP Right Cessation
- 1997-02-21 DK DK97301172T patent/DK0792643T3/da active
- 1997-02-21 ES ES97301172T patent/ES2172748T3/es not_active Expired - Lifetime
- 1997-02-21 EP EP97301172A patent/EP0792643B1/de not_active Expired - Lifetime
- 1997-02-21 DE DE69711972T patent/DE69711972T2/de not_active Expired - Fee Related
- 1997-02-21 PT PT97301172T patent/PT792643E/pt unknown
- 1997-02-21 AT AT97301172T patent/ATE216239T1/de not_active IP Right Cessation
- 1997-02-24 JP JP9039071A patent/JPH09316003A/ja active Pending
- 1997-02-26 CA CA002198564A patent/CA2198564C/en not_active Expired - Fee Related
- 1997-02-27 CN CN97102574A patent/CN1081460C/zh not_active Expired - Fee Related
- 1997-02-27 ZA ZA971717A patent/ZA971717B/xx unknown
- 1997-02-28 AU AU15010/97A patent/AU724327B2/en not_active Ceased
- 1997-02-28 KR KR1019970006780A patent/KR970061252A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| ZA971717B (en) | 1998-08-27 |
| PT792643E (pt) | 2002-08-30 |
| IL120264A0 (en) | 1997-06-10 |
| CN1168794A (zh) | 1997-12-31 |
| CA2198564A1 (en) | 1997-08-29 |
| CA2198564C (en) | 2000-06-27 |
| DE69711972T2 (de) | 2002-08-29 |
| EP0792643B1 (de) | 2002-04-17 |
| AU1501097A (en) | 1997-09-04 |
| US6127367A (en) | 2000-10-03 |
| CN1081460C (zh) | 2002-03-27 |
| EP0792643A1 (de) | 1997-09-03 |
| DE69711972D1 (de) | 2002-05-23 |
| AU724327B2 (en) | 2000-09-14 |
| MX9701533A (es) | 1998-06-30 |
| ES2172748T3 (es) | 2002-10-01 |
| DK0792643T3 (da) | 2002-07-22 |
| JPH09316003A (ja) | 1997-12-09 |
| KR970061252A (ko) | 1997-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE216239T1 (de) | Verwendung eines aldose-reduktase-inhibitors zur verminderung nicht-kardiologischer gewebeschäden | |
| SE0004112D0 (sv) | Stötfångarskena | |
| DE59812714D1 (de) | Optische anordnung zur symmetrierung der strahlung eines oder mehrerer übereinander angeordneter hochleistungsdiodenlaser | |
| AR031130A1 (es) | N-acilsulfonamidas promotoras de la apoptosis | |
| TR200200129T2 (tr) | Hepatit C inhibitörü tri-peptidler | |
| ATE161536T1 (de) | Neue mercaptoacetylamid-derivate zur verwendung als enkephalinase- und ace-hemmer | |
| AR015379A1 (es) | Ascorbil-fosforil-colesterol | |
| NO952977L (no) | Aminoduhydro-oksopurinyl-metoksypropandiolderivater | |
| FI961797L (fi) | Stabiloitu prostaglandiini E1 | |
| HK168195A (en) | Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors | |
| AR029984A1 (es) | Metodo para reducir las exacerbaciones asociadas copd ambito | |
| EP1459756A4 (de) | Entfernungspromotor und hemmer für apoptosiszellen in vivo | |
| DK0791355T3 (da) | Fremgangsmåde til reduktion af vævsbeskadigelse forbundet med iskæmi | |
| AU7358691A (en) | Tenidap as an inhibitor of the release of elastage by neutrophils | |
| WO2001079915A8 (en) | Diffraction grating in the whispering gallery mount | |
| FI924440A7 (fi) | Heterosykliset yhdisteet aldoosireduktaasi-inhibiitteinä | |
| WO2001087848A3 (en) | Synthesis procedure for biphenylimidazolyl-(1)-phenylmethane and related compounds | |
| DE50004488D1 (de) | System zur hydraulischen verstellung der übersetzung eines cvt | |
| DK0721781T3 (da) | Reduktion af fedtvæv under anvendelse af kollagenase | |
| DE69830298D1 (de) | Verwendung eines Kristallwachstumsinhibitors zur Verminderung der Abreibung von Geweben | |
| FI960371A7 (fi) | Tiatsolijohdannaisia lipoksigenaasi-inhibiittoreina | |
| RU96108459A (ru) | Антифриз | |
| CA2109516A1 (en) | Inhibitors of cathepsin g and elastase for preventing connective tissue degradation | |
| ATE166586T1 (de) | Ganzkörper-bräunungsgerät | |
| UA49438A (uk) | Спосіб відтинання надлишку низведеної кишки |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |